scholarly journals Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

2007 ◽  
Vol 44 (Supplement_2) ◽  
pp. S27-S72 ◽  
Author(s):  
Lionel A. Mandell ◽  
Richard G. Wunderink ◽  
Antonio Anzueto ◽  
John G. Bartlett ◽  
G. Douglas Campbell ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Community Acquired Pneumonia ◽  
American Thoracic Society ◽  
Consensus Guidelines

scholarly journals Clinical Guideline Highlights for the Hospitalist: 2019 American Thoracic Society/Infectious Disease Society of America Update on Community-Acquired Pneumonia

2020 ◽  
Vol 15 (12) ◽  
pp. 743-745
Author(s):  
Christopher D Jackson ◽  
Desiree C Burroughs-Ray ◽  
Nathan A Summers
Keyword(s):  
Infectious Disease ◽  
Infectious Diseases ◽  
Clinical Guideline ◽  
Target Population ◽  
Community Acquired Pneumonia ◽  
American Thoracic Society ◽  
Funding Source ◽  
Consensus Guidelines ◽  
Release Date ◽  
Immunocompetent Adult

GUIDELINE TITLE: Diagnosis and Treatment of Adults with Community Acquired Pneumonia: An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America RELEASE DATE: October 2019 PRIOR VERSION: 2007 Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults DEVELOPER: American Thoracic Society and Infectious Diseases Society of America FUNDING SOURCE: American Thoracic Society and Infectious Diseases Society of America TARGET POPULATION: Immunocompetent adult patients with community-acquired pneumonia

scholarly journals 42. A Pharmacist-Led Intervention to Decrease Anaerobic Coverage for Hospitalized Patients with Community-Acquired Pneumonia

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S44-S45
Author(s):  
Maxx O Enzmann ◽  
Courtney M Pagels ◽  
Emily J Perry ◽  
Justin Jones ◽  
Paul Carson
Keyword(s):  
Infectious Diseases ◽  
Antimicrobial Stewardship ◽  
Community Acquired Pneumonia ◽  
Lung Abscess ◽  
American Thoracic Society ◽  
Hospitalized Patients ◽  
Guidance Document ◽  
Antibiotic Exposure ◽  
Antibiotic Regimen ◽  
Days Of Therapy

Abstract Background Community-acquired pneumonia (CAP) is frequently mis-categorized as aspiration pneumonia, prompting the addition of anaerobic coverage to the antibiotic regimen. In our institution, this usually takes the form of adding metronidazole to ceftriaxone. The 2019 American Thoracic Society and Infectious Diseases Society of America CAP guidelines recommend anaerobic coverage only for hospitalized patients with a suspected lung abscess or empyema. The objective of this study was to determine if a pharmacist-led workflow could increase adherence to the 2019 CAP guideline recommendations by limiting anaerobic coverage to those rare occasions. Methods The hospital antimicrobial stewardship committee approved a pharmacist workflow and guidance document which outlines criteria to evaluate appropriateness of anaerobic coverage for hospitalized patients with CAP and no other indications for antibiotics. If anaerobic coverage is not indicated, the pharmacist submits a standardized message to the treating provider via the electronic medical record, recommending discontinuation of metronidazole. This workflow was implemented on October 3, 2019. Metronidazole days of therapy (DOT) per 1000 patient days in quarters 1 through 4 of 2019 and quarter 1 of 2020 were collected as well as percent acceptance of documented pharmacist interventions from October 3, 2019 until March 31, 2020. Results Between October 3, 2019 and March 31, 2020, a total of 221 interventions were made by pharmacists to discontinue metronidazole in hospitalized CAP patients where anaerobic coverage was not indicated. Out of those 221 interventions, 164 (74%) were accepted by providers and only 57 (26%) were rejected. The DOT per 1000 patient days of metronidazole was assessed for the three quarters prior to our intervention and the two quarters after the intervention. Compared to the three quarters prior, metronidazole DOT per 1000 patient days decreased by 26.6% for the two quarters following implementation of the pharmacist-led intervention (Figure 1). Figure 1: Metronidazole DOT per 1000 patient days from January 1, 2019 through March 31, 2020. Vertical line indicates when pharmacist workflow was implemented. Conclusion A pharmacist antimicrobial stewardship intervention at our institution increased adherence to CAP guidelines and decreased unnecessary antibiotic exposure in hospitalized CAP patients when anaerobic coverage was not indicated. Disclosures All Authors: No reported disclosures

scholarly journals Severe Community‐Acquired Pneumonia: Validation of the Infectious Diseases Society of America/American Thoracic Society Guidelines to Predict an Intensive Care Unit Admission

2009 ◽  
Vol 48 (4) ◽  
pp. 377-385 ◽  
Author(s):  
Adamantia Liapikou ◽  
Miquel Ferrer ◽  
Eva Polverino ◽  
Valentina Balasso ◽  
Mariano Esperatti ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Infectious Diseases ◽  
Intensive Care Unit Admission ◽  
Community Acquired Pneumonia ◽  
American Thoracic Society ◽  
Severe Community Acquired Pneumonia

scholarly journals Advances in community-acquired pneumonia

2020 ◽  
Vol 7 ◽  
pp. 204993612096960
Author(s):  
Barbara Jones ◽  
Grant Waterer
Keyword(s):  
Infectious Diseases ◽  
Standard Of Care ◽  
Community Acquired Pneumonia ◽  
American Thoracic Society ◽  
Long Term Outcomes ◽  
Gradual Improvement ◽  
The Past ◽  
Management Issues

Community-acquired pneumonia is one of the commonest and deadliest of the infectious diseases, yet our understanding of it remains relatively poor. The recently published American Thoracic Society and Infectious Diseases Society of America Community-acquired pneumonia guidelines acknowledged that most of what we accept as standard of care is supported only by low quality evidence, highlighting persistent uncertainty and deficiencies in our knowledge. However, progress in diagnostics, translational research, and epidemiology has changed our concept of pneumonia, contributing to a gradual improvement in prevention, diagnosis, treatment, and outcomes for our patients. The emergence of considerable evidence about adverse long-term health outcomes in pneumonia survivors has also challenged our concept of pneumonia as an acute disease and what treatment end points are important. This review focuses on advances in the research and care of community-acquired pneumonia in the past two decades. We summarize the evidence around our understanding of pathogenesis and diagnosis, discuss key contentious management issues including the role of procalcitonin and the use or non-use of corticosteroids, and explore the relationships between pneumonia and long-term outcomes including cardiovascular and cognitive health.

Sign in / Sign up

Export Citation Format

Share Document